BioStock: Positive phase I results for Saniona

The results are in from biopharma Saniona’s phase I clinical trial with SAN711 and they are positive. Data from the trial demonstrated that SAN711 was safe and well-tolerated across all dosing cohorts with a favourable absorption and distribution profile. With these results, the path lies open for continued clinical development of SAN711. BioStock reached out to Saniona’s CEO to comment the results.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/positive-phase-i-results-for-saniona/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se